Age-Specific Trends of Invasive Cervical Cancer Incidence in British Columbia, Canada, 1971-2017.

Canada cancer control and prevention cancer incidence cervical cancer elimination population surveillance

Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
18 08 2023
Historique:
received: 07 07 2023
revised: 08 08 2023
accepted: 16 08 2023
medline: 28 8 2023
pubmed: 25 8 2023
entrez: 25 8 2023
Statut: epublish

Résumé

This study examined invasive cervical cancer (ICC) incidence trends in British Columbia (BC) by age and stage-at-diagnosis relative to World Health Organization ICC elimination targets (4 per 100,000 persons). Incident ICC cases (1971-2017) were obtained from the BC Cancer Registry. Annual age-standardized incidence rates (ASIRs) per 100,000 persons were generated using the direct method. ASIRs were examined among all ages 15+ years and eight age groups using Joinpoint Regression with the Canadian 2011 standard population. Standardized rate ratios (SRRs) compared stage II-IV (late) versus stage I (early) ASIRs by age (2010-2017). ICC ASIRs did not reach the elimination target. ASIRs declined from 18.88 to 7.08 per 100,000 persons (1971-2017). Stronger declines were observed among ages 45+ years, with the largest decline among ages 70-79 years (AAPC = -3.2%, 95% CI = -3.9% to -2.6%). Among ages 25-69 years, varying levels of attenuation in declining trends and stabilization were observed since the 1980s. SRRs indicated higher rates of late-stage ICC among ages 55+ years (SRR-55-69 years = 1.34, 95% CI = 1.08-1.71). Overall, ICC incidence declined in BC since 1971 but did not reach the elimination target. The pace of decline varied across age groups and increased with age. Continued efforts are needed to progress cervical cancer elimination among all age groups.

Identifiants

pubmed: 37623038
pii: curroncol30080557
doi: 10.3390/curroncol30080557
pmc: PMC10453046
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7692-7705

Références

Gynecol Oncol. 2012 Dec;127(3):611-5
pubmed: 22922530
CMAJ. 2019 Nov 18;191(46):E1262-E1273
pubmed: 31740536
J Obstet Gynaecol Can. 2013 Jul;35(7):620-626
pubmed: 23876639
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):641-52
pubmed: 23549400
J Infect Dis. 2020 Jan 1;221(1):81-90
pubmed: 31504649
Lancet. 2020 Feb 22;395(10224):591-603
pubmed: 32007142
BMJ. 2015 Jun 15;350:h2729
pubmed: 26077735
J Obstet Gynaecol Can. 2012 Dec;34(12):1167-1176
pubmed: 23231799
CMAJ. 2022 May 2;194(17):E601-E607
pubmed: 35500919
CMAJ Open. 2021 Apr 22;9(2):E424-E432
pubmed: 33888548
Curr Oncol. 2022 Feb 14;29(2):1117-1122
pubmed: 35200594
Acta Obstet Gynecol Scand. 2021 Aug;100(8):1364-1368
pubmed: 33866548
Cancer Causes Control. 2015 Aug;26(8):1105-16
pubmed: 26033777
Br J Cancer. 2011 Jun 28;105(1):177-84
pubmed: 21654675
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Cancer. 2004 Mar 1;100(5):1035-44
pubmed: 14983500
CMAJ. 2013 Jan 8;185(1):35-45
pubmed: 23297138
J Obstet Gynaecol Can. 2019 Dec;41 Suppl 2:S177-S180
pubmed: 31785651
Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9
pubmed: 16172231
Cancer. 2017 Dec 15;123 Suppl 24:5119-5137
pubmed: 29205300
Lancet Public Health. 2019 Jan;4(1):e19-e27
pubmed: 30291040
Cancer Causes Control. 1997 Sep;8(5):755-63
pubmed: 9328198
Cancer Med. 2019 Jan;8(1):418-427
pubmed: 30600650
BMJ Open. 2018 Feb 23;8(2):e019005
pubmed: 29476028
Int J Gynecol Cancer. 2001 Jan-Feb;11(1):24-31
pubmed: 11285030
BMC Public Health. 2012 Nov 16;12:992
pubmed: 23158654
Br J Cancer. 2013 Jul 9;109(1):35-41
pubmed: 23820257
Eur J Cancer. 2013 Oct;49(15):3262-73
pubmed: 23751569
Health Promot Chronic Dis Prev Can. 2019 Nov;39(11):310-314
pubmed: 31729314
Cancer Causes Control. 2017 Oct;28(10):1105-1116
pubmed: 28887646
Lancet Public Health. 2020 Apr;5(4):e213-e222
pubmed: 32057315
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):677-86
pubmed: 15767349
Lancet Glob Health. 2020 Feb;8(2):e191-e203
pubmed: 31812369
BMC Womens Health. 2021 Mar 18;21(1):110
pubmed: 33736628
IARC Sci Publ. 1991;(95):126-58
pubmed: 1894318
Am J Prev Med. 2017 Sep;53(3):392-395
pubmed: 28473240
Lancet Oncol. 2019 Mar;20(3):394-407
pubmed: 30795950
Prev Med. 2019 Jun;123:316-323
pubmed: 31002830
Chronic Dis Inj Can. 2013 Mar;33(2):69-80
pubmed: 23470172
J Womens Health (Larchmt). 2012 Oct;21(10):1031-7
pubmed: 22816437

Auteurs

Nivedha Raveinthiranathan (N)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.

Jonathan Simkin (J)

Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Robine Donken (R)

School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Women's Health Research Institute, BC Women's Hospital and Health Service, Vancouver, BC V6H 3N1, Canada.
Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, BC V5Z 4H4, Canada.

Gina Ogilvie (G)

Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Women's Health Research Institute, BC Women's Hospital and Health Service, Vancouver, BC V6H 3N1, Canada.

Laurie Smith (L)

Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Women's Health Research Institute, BC Women's Hospital and Health Service, Vancouver, BC V6H 3N1, Canada.

Dirk Van Niekerk (D)

Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Cervical Cancer Screening Program, BC Cancer, Vancouver, BC V5Z 1G1, Canada.

Marette Lee (M)

Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.
Women's Health Research Institute, BC Women's Hospital and Health Service, Vancouver, BC V6H 3N1, Canada.

Ryan R Woods (RR)

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
Cancer Control Research, BC Cancer, Vancouver, BC V5Z 1L3, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH